Table 1 Comparison of clinico-pathological characteristics between patients with de novo and acquired resistance to 1st line endocrine therapy
| Â | Acquired resistance | de novo resistance | ||
|---|---|---|---|---|
Total = 223 (100%) | To 1st line | To 1st line | ||
CB (Clinical Benefit) | 159 (71.3%) | 64 (28.7) | ||
Median duration of treatment in months | 15.7+ | 2.9 | ||
Median Age (Range) at metastasis in years | 63.5 (30–89) | 61.5 (32–87) | ||
DFI (months) | 58.0 (0–294) | 36.5 (0–324) | ||
Median Age (Range) at primary cancer in years | 56.0 (26–86) | 55.0 (28–87) | ||
Maximum Size (Range) of tumour in mm. | 24 (4–110) | 27 (10–110) | ||
Minimum Size (Range) of tumour in mm. | 20 (2–70) | 25 (10–75) | ||
Histological lymph node stage(no. of positive nodes) | 1 (0) | 39.8 | 1 (0) | 37.5 |
|  | 2 (1–3) | 41.8 | 2 (1–3) | 37.5 |
|  | 3 (≥4) | 18.4 | 3 (≥4) | 25.0 |
Grade (Elston/Ellis) | 1 | 11.6 | 1 | 9.3 |
| Â | 2 | 49.3 | 2 | 37.0 |
| Â | 3 | 30.4 | 3 | 40.7 |
| Â | unknown | 8.7 | unknown | 13.0 |
Vascular invasion | 44.1% | 50.0 | ||
Bony metastasis | 61.5 | 60.3 | ||
Lung metastasis | 21.4 | 23.9 | ||
Pleural metastasis | 25.5 | 47.8 | ||
Lymphangitis | 2.1 | 15.2 | ||
Liver metastasis | 10.4 | 41.8 | ||
Other metastasis | 35.2 | 28.8 | ||